Gritstone Oncology is a leader in personalized cancer immunotherapies and is developing novel RNA-based neoantigen immunotherapy drug candidates


Gritstone Oncology was granted worldwide access to Arbutus’ portfolio of proprietary and clinically validated lipid nanoparticle (LNP) products and associated intellectual property to deliver Gritstone’s RNA-based neoantigen immunotherapy products to tackle fundamental challenges at the intersection of cancer genomics, immunology, and immunotherapy design. Gritstone’s initial goal is to leverage deep learning to identify and deploy therapeutic neoantigens from individual patients’ tumors to develop novel treatments for lung and gastric cancer.